At the forefront of oncology
Ryvu Therapeutics discovers and develops small molecule therapies that address high value emerging targets in oncology.
Our pipeline is built from internally-discovered candidates which make use of diverse therapeutic mechanisms, including programs directed at targets in the areas of transcriptional regulation, synthetic lethality and immuno-oncology.
WE BELIEVE IN SCIENCE
Clinical projects
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.
PRECISION ON THE TARGET
Synthetic Lethality
One of the challenges in the development of new oncology therapeutics is the limited number of protein targets known to be addressable with small molecules. Synthetic lethality allows the identification of novel protein targets and mechanisms of cancer cell sensitivity that can be used therapeutically.
Explore projects
SHAPE THE FUTURE
ONCO Prime
New possibilities for personalized anticancer therapy based on the culture of primary cells from the patient, omics characterization and functional tests.
Explore projects
TRUSTED PARTNERS
Immuno-oncology Collaborationst
One of the challenges in the development of new oncology therapeutics is the limited number of protein targets known to be addressable with small molecules. Synthetic lethality allows the identification of novel protein targets and mechanisms of cancer cell sensitivity that can be used therapeutically.
Work with us
WE BELIEVE IN SCIENCE
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.
Contact us
Careers
JOIN OUR TEAM
Be a part of our mission to develop groundbreaking therapies and transform patient care. Explore exciting career opportunities with us and help shape the future of medicine.
See open positions
Publications
- pdf file
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Download - pdf file
Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers
Download - pdf file
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
Download - pdf file
Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells
Download
- pdf file
Ryvu Therapeutics Q3 2024 Report
Download - pdf file
Ryvu Therapeutics Financial Statements Q3 2024
Download
- pdf file
Ryvu Therapeutics H1 2024 Report
Download - pdf file
Ryvu Therapeutics Financial Statements H1 2024
Download - pdf file
Independent Auditor’s Report On Review Of Interim Financial Statements
Download
- pdf file
Discovery of novel small molecule STING agonists as a new cancer immunotherapy
Download - pdf file
Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy
Download
- pdf file
Current Report ESPI 5/2024
Download
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator
for a RYVU trial, or would like information about becoming an investigator, please contact us
investigators@ryvu.com or use contact form.
